Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20660906 | 0.77 | SMN1; SMN2 (0.39) | PRKCIDHFRKDM4EALDH1A1GAA | |
| SCHEMBL30592233 | 0.77 | SMN1; SMN2 (0.39) | PRKCIDHFRKDM4EALDH1A1GAA | |
| SCHEMBL1097841 | 0.77 | PIK3CB (0.47) | PRKCIDHFRHSD11B1PIK3CBCYP2A6 | |
| SCHEMBL31036108 | 0.77 | PIK3CB (0.47) | PRKCIDHFRHSD11B1PIK3CBCYP2A6 | |
| SCHEMBL16417124 | 0.77 | PRKCI (0.38) | PRKCIDHFRKDM4EALDH1A1GAA | |
| SCHEMBL16302770 | 0.75 | EGFR (0.37) | CYP1A2KDM4EALDH1A1GAARAB9A | |
| SCHEMBL7706466 | 0.74 | PRKCI (0.36) | PRKCIDHFRKDM4EALDH1A1GAA | |
| SCHEMBL17463068 | 0.74 | CYP1A2 (0.36) | CYP1A2KDM4EALDH1A1RAB9ALMNA | |
| SCHEMBL23554638 | 0.72 | CCR1 (0.41) | PRKCIDHFRALDH1A1HSD11B1PIK3CB | |
| SCHEMBL30547717 | 0.72 | MGAM (0.47) | PRKCIDHFRKDM4EALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192738-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-22 | — | — | US | disclosed |
| EP-3172214-B1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-9828373-B2 | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-11-28 | — | — | US | disclosed |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20150045551-A1 | FUSED AZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-02-12 | — | — | US | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | CYP1A2 2432/4885PRKCI 902/4885DHFR 2852/4885 |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | CDK6, CDK4, CDK7 | CYP1A2 2108/4885PRKCI 949/4885DHFR 263/4885 |
| US-20150045551-A1 | FUSED AZOLE DERIVATIVE | AVPR1B, AVPR1A, GRIN2B | CYP1A2 838/4885PRKCI 1709/4885DHFR 367/4885 |
| US-20230192738-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OPRM1, OPRD1, OXER1 | CYP1A2 998/4885PRKCI 4488/4885DHFR 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.